Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review [PDF]
Pharmaceuticals, 2021 Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD ...
Gniewko Więckiewicz +4 more
doaj +6 more sources
Molecules, 2020 The rapid dispersion of new psychoactive substances (NPS) presents challenges to customs services and analytical laboratories, which are involved in their detection and characterization.
Emmanouil Tsochatzis +5 more
doaj +6 more sources
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. [PDF]
J Psychopharmacol, 2023 Background: Growing numbers of people are using psychedelics for personal psychotherapy outside clinical settings, but research on such use is scarce.
Kopra EI +5 more
europepmc +3 more sources
Lysergic acid diethylamide: a drug of ‘use’? [PDF]
Therapeutic Advances in Psychopharmacology, 2016 Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some ‘benevolent’
Saibal Das +2 more
exaly +4 more sources
Use of Lysergic Acid Diethylamide by Major Depression Status. [PDF]
JAMA Psychiatry, 2023 Importance Renewed interest in the clinical potential of hallucinogens may lead people with depression to a generally more positive view of the use of lysergic acid diethylamide (LSD).
Walsh CA +4 more
europepmc +2 more sources
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review. [PDF]
CNS Drugs, 2023 Background and Objectives The renewed interest in psychedelic research provides growing evidence of potentially unique effects on various aspects of reward processing systems.
Pouyan N +5 more
europepmc +2 more sources
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. [PDF]
Neuropsychopharmacology, 2023 Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of these substances is lacking.
Ley L +13 more
europepmc +2 more sources
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. [PDF]
Neuropsychopharmacology, 2023 Psychedelics have emerged as promising candidate treatments for various psychiatric conditions, and given their clinical potential, there is a need to identify biomarkers that underlie their effects. Here, we investigate the neural mechanisms of lysergic
Bedford P +11 more
europepmc +2 more sources
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. [PDF]
Neuropsychopharmacology, 2022 Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their ...
Holze F +12 more
europepmc +2 more sources
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). [PDF]
J Psychopharmacol, 2022 Background: Recreational lysergic acid diethylamide (LSD) use is growing in popularity amid increasing research interest on psychedelics and their possible therapeutic potential yet; the potent psychotropic effects of LSD may result in adverse reactions ...
Kopra EI +6 more
europepmc +2 more sources